Reports
Global Duchenne Muscular Dystrophy (DMD) Treatment Market: By Therapeutic Approaches: Molecular-based Therapies, Steroid Therapy, Others; By Distribution Channel: Hospitals, Retail and Online Pharmacies; By End Users; Regional Analysis; Market Dynamics: SWOT Analysis, Porter’s Five Forces Analysis; Competitive Landscape; 2024-2032
Global Duchenne Muscular Dystrophy (DMD) Treatment Market Outlook
The global market for Duchenne muscular dystrophy (DMD) treatment reached a value of about USD 1.15 million in 2021. The industry is further expected to grow at a CAGR of approximately 12.50% in the forecast period of 2024-2032 to reach a value of around USD 2.34 million by 2027.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
North America and Europe to be Significant Regional Markets for Duchenne Muscular Dystrophy (DMD) Treatment
North America and Europe are currently the two largest markets in the global Duchenne muscular dystrophy (DMD) treatment market as these are expected to account for a large proportion of the market in the forecast period. New product innovations, rising incidence of Duchenne muscular dystrophy, rise in the demand for early diagnosis, high healthcare expenditure, increasing investments in research and development of new treatment options, and government awareness programs are the major factors anticipated to propel the market growth in these regions. The United States is the dominant country in North America and is projected to maintain its lead due to rising disease incidence and the anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe.
Exon Skipping Segment Expected to Dominate the Market Growth
The increasing adoption of EXONDYS 51 has driven the segment growth. EXONDYS 51 refers to the first FDA-approved Duchenne muscular dystrophy treatment for patients who suffer from a confirmed genetic mutation in the dystrophin gene, which can be treated by skipping exon 51. It helps the body make a shorter form of the dystrophin protein in some patients. The internal deletions mainly cause Duchenne muscular dystrophy in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic methods is to mask an exon close to the site where the others are missing so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.
Also, the market players are increasingly focusing on frequent launches in exon-skipping technology, which is a significant factor driving the segment and propelling the growth of the Duchenne muscular dystrophy (DMD) treatment market. For instance, In December 2019, Sarepta’s exon-skipping drug, VYONDYS 53 (golodirsen), was approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.
Market Segmentations
Duchenne muscular dystrophy (DMD) is a hereditary condition that causes muscle weakening and deterioration. DMD is caused by a mutation in the gene that codes for the dystrophin protein, which is found in muscles. It is a rare muscular condition that usually affects men. Intellectual incapacity, muscle weakness, and walking and breathing difficulties are among the common symptoms.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Based on therapeutic approaches, the market is segmented into:
- Molecular-based Therapies
- Mutation Suppression
- Exon Skipping
- Steroid Therapy
- Other Therapeutic Approaches
The several distribution channels of the market are:
- Hospitals
- Retail and Online Pharmacies
The end-users of the market are:
- Hospitals
- Home Care Settings
- Clinics
The regional markets for the Duchenne muscular dystrophy (DMD) treatment market can be divided into North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa.
\
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Introduction of Novel Drugs and Therapies Augmenting the Market Growth
The major drivers in the global Duchenne muscular dystrophy (DMD) treatment market include the introduction of novel drugs and therapies, significant support from various firms for drug research, disease-modifying therapies, and support from patient advocacy groups on the regulatory approval process. An increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy and a broad product pipeline are likely to drive the global market growth during the forecast period. Mutation-specific therapies are expected to emerge as a breakthrough in the treatment of Duchenne muscular dystrophy. The increasing disease burden of Duchenne muscular dystrophy, increased investments in biopharmaceutical research and development to release novel disease therapeutics, and increased DMD awareness campaigns also contribute to the market's growth. Various organisations are involved in spreading awareness and investing in research and development to find an effective treatment for this disease, contributing to the global market growth. Other factors, such as constant research on gene therapy, stem cell therapy, and exon skipping drugs for the treatment of DMD, are expected to propel the market growth of DMD treatment. Additionally, favourable reimbursement policies and government initiatives supporting target-specific therapies are anticipated to fuel the market during the forecasted period.
Key Players in the Market for Global Duchenne Muscular Dystrophy (DMD) Treatment
The report gives a detailed analysis of the following key players in the global Duchenne muscular dystrophy (DMD) treatment market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:
- Pfizer Inc.
- Sarepta Therapeutics, Inc.
- PTC Therapeutics Inc.
- FibroGen, Inc
- F. Hoffmann-La Roche Ltd
- NS Pharma, Inc.
- Solid Biosciences Inc.
- Others
The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
|---|---|
| Base Year | 2023 |
| Historical Period | 2018-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Therapeutic Approaches |
|
| Breakup by Distribution Channel |
|
| Breakup by End Users |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
2 Report Coverage – Key Segmentation and Scope
3 Report Description
3.1 Market Definition and Outlook
3.2 Properties and Applications
3.3 Market Analysis
3.4 Key Players
4 Key Assumptions
5 Executive Summary
5.1 Overview
5.2 Key Drivers
5.3 Key Developments
5.4 Competitive Structure
5.5 Key Industrial Trends
6 Market Snapshot
6.1 Global
6.2 Regional
7 Opportunities and Challenges in the Market
8 Global Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
8.1 Key Industry Highlights
8.2 Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market (2018-2023)
8.3 Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast (2024-2032)
8.4 Global Duchenne Muscular Dystrophy (DMD) Treatment Market by Therapeutic Approaches
8.4.1 Molecular-based Therapies
8.4.1.1 Historical Trend (2018-2023)
8.4.1.2 Forecast Trend (2024-2032)
8.4.1.3 Breakup by Type
8.4.1.3.1 Mutation Suppression
8.4.1.3.2 Exon Skipping
8.4.2 Steroid Therapy
8.4.2.1 Historical Trend (2018-2023)
8.4.2.2 Forecast Trend (2024-2032)
8.4.3 Other Therapeutic Approaches
8.4.3.1 Historical Trend (2018-2023)
8.4.3.2 Forecast Trend (2024-2032)
8.5 Global Duchenne Muscular Dystrophy (DMD) Treatment Market by Distribution Channel
8.5.1 Hospitals
8.5.1.1 Historical Trend (2018-2023)
8.5.1.2 Forecast Trend (2024-2032)
8.5.2 Retail and Online Pharmacies
8.5.2.1 Historical Trend (2018-2023)
8.5.2.2 Forecast Trend (2024-2032)
8.6 Global Duchenne Muscular Dystrophy (DMD) Treatment Market by End Users
8.6.1 Hospitals
8.6.1.1 Historical Trend (2018-2023)
8.6.1.2 Forecast Trend (2024-2032)
8.6.2 Home Care Settings
8.6.2.1 Historical Trend (2018-2023)
8.6.2.2 Forecast Trend (2024-2032)
8.6.3 Clinics
8.6.3.1 Historical Trend (2018-2023)
8.6.3.2 Forecast Trend (2024-2032)
8.7 Global Duchenne Muscular Dystrophy (DMD) Treatment Market by Region
8.7.1 North America
8.7.1.1 Historical Trend (2018-2023)
8.7.1.2 Forecast Trend (2024-2032)
8.7.2 Europe
8.7.2.1 Historical Trend (2018-2023)
8.7.2.2 Forecast Trend (2024-2032)
8.7.3 Asia Pacific
8.7.3.1 Historical Trend (2018-2023)
8.7.3.2 Forecast Trend (2024-2032)
8.7.4 Latin America
8.7.4.1 Historical Trend (2018-2023)
8.7.4.2 Forecast Trend (2024-2032)
8.7.5 Middle East and Africa
8.7.5.1 Historical Trend (2018-2023)
8.7.5.2 Forecast Trend (2024-2032)
9 North America Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
9.1 United States of America
9.1.1 Historical Trend (2018-2023)
9.1.2 Forecast Trend (2024-2032)
9.2 Canada
9.2.1 Historical Trend (2018-2023)
9.2.2 Forecast Trend (2024-2032)
10 Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
10.1 United Kingdom
10.1.1 Historical Trend (2018-2023)
10.1.2 Forecast Trend (2024-2032)
10.2 Germany
10.2.1 Historical Trend (2018-2023)
10.2.2 Forecast Trend (2024-2032)
10.3 France
10.3.1 Historical Trend (2018-2023)
10.3.2 Forecast Trend (2024-2032)
10.4 Italy
10.4.1 Historical Trend (2018-2023)
10.4.2 Forecast Trend (2024-2032)
10.5 Others
11 Asia Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
11.1 China
11.1.1 Historical Trend (2018-2023)
11.1.2 Forecast Trend (2024-2032)
11.2 Japan
11.2.1 Historical Trend (2018-2023)
11.2.2 Forecast Trend (2024-2032)
11.3 India
11.3.1 Historical Trend (2018-2023)
11.3.2 Forecast Trend (2024-2032)
11.4 ASEAN
11.4.1 Historical Trend (2018-2023)
11.4.2 Forecast Trend (2024-2032)
11.5 Australia
11.5.1 Historical Trend (2018-2023)
11.5.2 Forecast Trend (2024-2032)
11.6 Others
12 Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
12.1 Brazil
12.1.1 Historical Trend (2018-2023)
12.1.2 Forecast Trend (2024-2032)
12.2 Argentina
12.2.1 Historical Trend (2018-2023)
12.2.2 Forecast Trend (2024-2032)
12.3 Mexico
12.3.1 Historical Trend (2018-2023)
12.3.2 Forecast Trend (2024-2032)
12.4 Others
13 Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Market Analysis
13.1 Saudi Arabia
13.1.1 Historical Trend (2018-2023)
13.1.2 Forecast Trend (2024-2032)
13.2 United Arab Emirates
13.2.1 Historical Trend (2018-2023)
13.2.2 Forecast Trend (2024-2032)
13.3 Nigeria
13.3.1 Historical Trend (2018-2023)
13.3.2 Forecast Trend (2024-2032)
13.4 South Africa
13.4.1 Historical Trend (2018-2023)
13.4.2 Forecast Trend (2024-2032)
13.5 Others
14 Market Dynamics
14.1 SWOT Analysis
14.1.1 Strengths
14.1.2 Weaknesses
14.1.3 Opportunities
14.1.4 Threats
14.2 Porter’s Five Forces Analysis
14.2.1 Supplier’s Power
14.2.2 Buyer’s Power
14.2.3 Threat of New Entrants
14.2.4 Degree of Rivalry
14.2.5 Threat of Substitutes
14.3 Key Indicators for Demand
14.4 Key Indicators for Price
15 Competitive Landscape
15.1 Market Structure
15.2 Company Profiles
15.2.1 Pfizer Inc.
15.2.1.1 Company Overview
15.2.1.2 Product Portfolio
15.2.1.3 Demographic Reach and Achievements
15.2.1.4 Certifications
15.2.2 Sarepta Therapeutics, Inc.
15.2.2.1 Company Overview
15.2.2.2 Product Portfolio
15.2.2.3 Demographic Reach and Achievements
15.2.2.4 Certifications
15.2.3 PTC Therapeutics Inc.
15.2.3.1 Company Overview
15.2.3.2 Product Portfolio
15.2.3.3 Demographic Reach and Achievements
15.2.3.4 Certifications
15.2.4 FibroGen, Inc
15.2.4.1 Company Overview
15.2.4.2 Product Portfolio
15.2.4.3 Demographic Reach and Achievements
15.2.4.4 Certifications
15.2.5 F. Hoffmann-La Roche Ltd
15.2.5.1 Company Overview
15.2.5.2 Product Portfolio
15.2.5.3 Demographic Reach and Achievements
15.2.5.4 Certifications
15.2.6 NS Pharma, Inc.
15.2.6.1 Company Overview
15.2.6.2 Product Portfolio
15.2.6.3 Demographic Reach and Achievements
15.2.6.4 Certifications
15.2.7 Solid Biosciences Inc.
15.2.7.1 Company Overview
15.2.7.2 Product Portfolio
15.2.7.3 Demographic Reach and Achievements
15.2.7.4 Certifications
15.2.8 Others
16 Key Trends and Developments in the Market
List of Key Figures and Tables
1. Global Duchenne Muscular Dystrophy (DMD) Treatment Market: Key Industry Highlights, 2018 and 2032
2. Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Therapeutic Approaches (USD Million), 2018-2023
3. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Therapeutic Approaches (USD Million), 2024-2032
4. Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Distribution Channel (USD Million), 2018-2023
5. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Distribution Channel (USD Million), 2024-2032
6. Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup End Users (USD Million), 2018-2023
7. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by End Users (USD Million), 2024-2032
8. Global Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Region (USD Million), 2018-2023
9. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Region (USD Million), 2024-2032
10. North America Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
11. North America Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
12. Europe Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
13. Europe Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
14. Asia Pacific Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
15. Asia Pacific Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
16. Latin America Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
17. Latin America Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
18. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Historical Market: Breakup by Country (USD Million), 2018-2023
19. Middle East and Africa Duchenne Muscular Dystrophy (DMD) Treatment Market Forecast: Breakup by Country (USD Million), 2024-2032
20. Global Duchenne Muscular Dystrophy (DMD) Treatment Market Structure
Key Questions Answered in the Report
In 2021, the global market attained a value of nearly USD 1.15 million.
The market is projected to grow at a CAGR of 12.50% between 2024 and 2032.
The market is estimated to witness healthy growth in the forecast period of 2024-2032 to reach USD 2.34 million by 2027.
The major drivers of the market include the rising disease incidence, anticipated launch of promising pipeline candidates, significant support from various firms for drug research, increased investments in biopharmaceutical research and development to release novel disease therapeutics, increased DMD awareness campaigns, favourable reimbursement policies and government initiatives supporting target-specific treatments.
The introduction of novel drugs and therapies and an increase in the number of clinical trials are the key industry trends propelling the market's growth.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Based on therapeutic approaches, the market is segmented into molecular-based therapies and steroid therapy, among other therapeutic approaches. Molecular-based therapies are further divided into mutation suppression and exon skipping.
The several distribution channels of the market are hospitals, retail, and online pharmacies.
The end-users of the market are hospitals, home care settings, and clinics.
The major players in the industry include Pfizer Inc., Sarepta Therapeutics, Inc., PTC Therapeutics Inc., FibroGen, Inc, F. Hoffmann-La Roche Ltd, NS Pharma, Inc., and Solid Biosciences Inc., among others.
Analyst Review
The global Duchenne muscular dystrophy (DMD) treatment market attained a value of USD 1.15 million in 2021, driven by the introduction of novel drugs and therapies. Aided by the increased DMD awareness campaigns and an increase in the number of clinical trials, the market is expected to witness further growth in the forecast period of 2024-2032, growing at a CAGR of 12.50%. The market is projected to reach USD 2.34 million by 2027.
EMR’s meticulous research methodology delves deep into the market, covering the macro and micro aspects of the industry. Based on therapeutic approaches, the market is segmented into molecular-based therapies and steroid therapy, among other therapeutic approaches. Molecular-based treatments are further divided into mutation suppression and exon skipping. The several distribution channels of the market are hospitals, retail and online pharmacies. The end-users of the market are hospitals, home care settings, and clinics. The major regional markets for Duchenne muscular dystrophy (DMD) treatment are North America, Europe, the Asia Pacific, Latin America, the Middle East and Africa. The key players in the Duchenne muscular dystrophy (DMD) treatment market include Pfizer Inc., Sarepta Therapeutics, Inc., PTC Therapeutics Inc., FibroGen, Inc, F. Hoffmann-La Roche Ltd, NS Pharma, Inc., and Solid Biosciences Inc., among others.
EMR’s research methodology uses a combination of cutting-edge analytical tools and the expertise of their highly accomplished team, thus, providing their customers with market insights that are accurate, actionable, and help them remain ahead of their competition.
Purchase Options
Call us on
Purchase Full Report
Mini Report
$1699
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$2799
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$3999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$4999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER